ViraTherapeutics, an oncolytic virus biotech, was acquired by Boehringer Ingelheim in a bid to expand its presence in the field of immuno-oncology. Boehringer will use ViraTherapeutics' oncolytic virus therapies combined with cancer drugs in its development pipeline.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.